Sveriges mest populära poddar

Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-directed immunotherapies.

22 min•7 juli 2022

Today we’ll learn more about the risk of subsequent malignancies in patients treated with genetically modified immune effector cells, discuss how p53 immunohistochemistry can be a global readout for TP53 alterations in AML, and uncover the role of CD19-negative CD22-positive B-cell progenitors in immune escape from CD19-directed therapies.

Fler avsnitt av Blood Podcast

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

20 aug.•15 min

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

13 aug.•33 min

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

6 aug.•17 min

FLT3-ITD microclones in AML and Results from the RESET-PV trial

30 juli•14 min

Initial CHORUS data on HHT and ASH HematOmics Program

23 juli•26 min

IV Iron during Acute Infection and Revisiting iTTP Refractoriness

16 juli•17 min

A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies

9 juli•18 min

IV Iron Risks and Low-Dose AML Gains

2 juli•25 min

Orca-T for GVHD–free survival and Understanding VEXAS anemia

25 juni•23 min

Treating AML, Before and After Relapse

18 juni•16 min

Blood Podcast med American Society of Hematology finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.